We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · May 22, 2021

Ruxolitinib Cream for the Treatment of Atopic Dermatitis

Journal of the American Academy of Dermatology

 

Additional Info

Journal of the American Academy of Dermatology
Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Results From Two Phase 3, Randomized, Double-Blind Studies
J Am Acad Dermatol 2021 May 03;[EPub Ahead of Print], K Papp, JC Szepietowski, L Kircik, D Toth, LF Eichenfield, DYM Leung, SB Forman, ME Venturanza, K Sun, ME Kuligowski, EL Simpson

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading